Dynavax Technologies Corporation Patent applications |
Patent application number | Title | Published |
20160003807 | TLR8 TRANSGENIC ANIMALS - Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof. | 01-07-2016 |
20140127255 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 05-08-2014 |
20140094504 | HUMAN TOLL-LIKE RECEPTOR INHIBITORS AND METHODS OF USE THEREOF - Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9. | 04-03-2014 |
20130156814 | METHODS OF TREATMENT USING TLR7 AND/OR TLR9 INHIBITORS - The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9. | 06-20-2013 |
20120263755 | METHODS AND COMPOSITIONS FOR ELICITING AN IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS - The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof. | 10-18-2012 |
20120252051 | TLR8 TRANSGENIC ANIMALS - Provided herein are human Toll-like receptor 8 (TLR8)-expressing transgenic animals and methods of use thereof. | 10-04-2012 |
20120121622 | BIODEGRADABLE IMMUNOMODULATORY FORMULATIONS AND METHODS FOR USE THEREOF - The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier. | 05-17-2012 |
20110123561 | METHODS AND COMPOSITIONS FOR INDUCTION OR PROMOTION OF IMMUNE TOLERANCE - The invention provides non-immunostimulatory polynucleotide antigen conjugates and methods for treating unwanted immune reactions in individuals using the non-immunostimulatory polynucleotide antigen conjugates. | 05-26-2011 |
20110038896 | Biodegradable immunomodulatory formulations and methods for use thereof - The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier. | 02-17-2011 |
20110003885 | METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES AND AUTOIMMUNITY - The application relates to the use of immunoregulatory polynucleotides and/or immunoregulatory compounds in combination with other therapeutic agents. The application further relates to immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence. It also relates to the administration of the immunoregulatory polynucleotides and/or immunoregulatory compounds comprising a modified immunoregulatory sequence to regulate an immune response. | 01-06-2011 |
20100183666 | METHODS OF REDUCING PAPILLOMAVIRUS INFECTION USING IMMUNOMODULATORY POLYNUCLEOTIDE SEQUENCES - The invention provides methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection. | 07-22-2010 |